340 related articles for article (PubMed ID: 28336527)
21. A phase 1b trial of selinexor, a first-in-class selective inhibitor of nuclear export (SINE), in combination with doxorubicin in patients with advanced soft tissue sarcomas (STS).
Lewin J; Malone E; Al-Ezzi E; Fasih S; Pedersen P; Accardi S; Gupta A; Abdul Razak A
Eur J Cancer; 2021 Feb; 144():360-367. PubMed ID: 33418486
[TBL] [Abstract][Full Text] [Related]
22. Phase I study of cladribine, cytarabine (Ara-C), granulocyte colony stimulating factor (G-CSF) (CLAG Regimen) and simultaneous escalating doses of imatinib mesylate (Gleevec) in relapsed/refractory AML.
Walker AR; Komrokji RS; Ifthikharuddin J; Messina P; Mulford D; Becker M; Friedberg J; Oliva J; Phillips G; Liesveld JL; Abboud C
Leuk Res; 2008 Dec; 32(12):1830-6. PubMed ID: 18571721
[TBL] [Abstract][Full Text] [Related]
23. Decitabine priming enhances the antileukemic effects of exportin 1 (XPO1) selective inhibitor selinexor in acute myeloid leukemia.
Ranganathan P; Yu X; Santhanam R; Hofstetter J; Walker A; Walsh K; Bhatnagar B; Klisovic R; Vasu S; Phelps MA; Devine S; Shacham S; Kauffman M; Marcucci G; Blum W; Garzon R
Blood; 2015 Apr; 125(17):2689-92. PubMed ID: 25716206
[TBL] [Abstract][Full Text] [Related]
24. Phase I/II study of dasatinib in combination with decitabine in patients with accelerated or blast phase chronic myeloid leukemia.
Abaza Y; Kantarjian H; Alwash Y; Borthakur G; Champlin R; Kadia T; Garcia-Manero G; Daver N; Ravandi F; Verstovsek S; Burger J; Estrov Z; Ohanian M; Lim M; Pemmaraju N; Jabbour E; Cortes J
Am J Hematol; 2020 Nov; 95(11):1288-1295. PubMed ID: 32681739
[TBL] [Abstract][Full Text] [Related]
25. XPO1 Inhibition using Selinexor Synergizes with Chemotherapy in Acute Myeloid Leukemia by Targeting DNA Repair and Restoring Topoisomerase IIα to the Nucleus.
Ranganathan P; Kashyap T; Yu X; Meng X; Lai TH; McNeil B; Bhatnagar B; Shacham S; Kauffman M; Dorrance AM; Blum W; Sampath D; Landesman Y; Garzon R
Clin Cancer Res; 2016 Dec; 22(24):6142-6152. PubMed ID: 27358488
[TBL] [Abstract][Full Text] [Related]
26. Safety and preliminary efficacy of venetoclax with decitabine or azacitidine in elderly patients with previously untreated acute myeloid leukaemia: a non-randomised, open-label, phase 1b study.
DiNardo CD; Pratz KW; Letai A; Jonas BA; Wei AH; Thirman M; Arellano M; Frattini MG; Kantarjian H; Popovic R; Chyla B; Xu T; Dunbar M; Agarwal SK; Humerickhouse R; Mabry M; Potluri J; Konopleva M; Pollyea DA
Lancet Oncol; 2018 Feb; 19(2):216-228. PubMed ID: 29339097
[TBL] [Abstract][Full Text] [Related]
27. Oral Selinexor as Maintenance Therapy After First-Line Chemotherapy for Advanced or Recurrent Endometrial Cancer.
Vergote I; Pérez-Fidalgo JA; Hamilton EP; Valabrega G; Van Gorp T; Sehouli J; Cibula D; Levy T; Welch S; Richardson DL; Guerra EM; Scambia G; Henry S; Wimberger P; Miller DS; Klat J; Martínez-Garcia J; Raspagliesi F; Pothuri B; Romero I; Bergamini A; Slomovitz B; Schochter F; Høgdall E; Fariñas-Madrid L; Monk BJ; Michel D; Kauffman MG; Shacham S; Mirza MR; Makker V;
J Clin Oncol; 2023 Dec; 41(35):5400-5410. PubMed ID: 37669480
[TBL] [Abstract][Full Text] [Related]
28. Combinatorial targeting of XPO1 and FLT3 exerts synergistic anti-leukemia effects through induction of differentiation and apoptosis in
Zhang W; Ly C; Ishizawa J; Mu H; Ruvolo V; Shacham S; Daver N; Andreeff M
Haematologica; 2018 Oct; 103(10):1642-1653. PubMed ID: 29773601
[TBL] [Abstract][Full Text] [Related]
29. Long-term follow-up of efficacy and safety of selinexor maintenance treatment in patients with TP53wt advanced or recurrent endometrial cancer: A subgroup analysis of the ENGOT-EN5/GOG-3055/SIENDO study.
Makker V; Perez-Fidalgo JA; Valabrega G; Hamilton E; Van Gorp T; Sehouli J; Regináčová K; Richardson DL; Perri T; Oza AM; Miller DS; Alía EMG; De Giorgi U; Henry S; Spitz DL; Wimberger P; Bednaříková M; Chon HS; Martínez-Garcia J; Pisano C; Berek JS; Romero I; Scambia G; Fariñas-Madrid L; Buscema J; Schochter F; Li K; Kalyanapu P; Walker CJ; Vergote I
Gynecol Oncol; 2024 Jun; 185():202-211. PubMed ID: 38834399
[TBL] [Abstract][Full Text] [Related]
30. International phase 3 study of azacitidine vs conventional care regimens in older patients with newly diagnosed AML with >30% blasts.
Dombret H; Seymour JF; Butrym A; Wierzbowska A; Selleslag D; Jang JH; Kumar R; Cavenagh J; Schuh AC; Candoni A; Récher C; Sandhu I; Bernal del Castillo T; Al-Ali HK; Martinelli G; Falantes J; Noppeney R; Stone RM; Minden MD; McIntyre H; Songer S; Lucy LM; Beach CL; Döhner H
Blood; 2015 Jul; 126(3):291-9. PubMed ID: 25987659
[TBL] [Abstract][Full Text] [Related]
31. Selinexor in combination with weekly paclitaxel in patients with metastatic solid tumors: Results of an open label, single-center, multi-arm phase 1b study with expansion phase in ovarian cancer.
Westin SN; Fu S; Tsimberidou A; Piha-Paul S; Akhmedzhanov F; Yilmaz B; McQuinn L; Brink AL; Gong J; Leung CH; Lin H; Hong DS; Pant S; Carter B; Jazaeri A; Gershenson D; Sood AK; Coleman RL; Shah J; Meric-Bernstam F; Naing A
Gynecol Oncol; 2023 Jan; 168():76-82. PubMed ID: 36423446
[TBL] [Abstract][Full Text] [Related]
32. Efficacy and safety of selinexor in the treatment of AML: A protocol for systematic review and meta-analysis.
Yu L; Yin X; Si Y; Wang Y; Wang J; Cui S
Medicine (Baltimore); 2021 Dec; 100(49):e27884. PubMed ID: 34889237
[TBL] [Abstract][Full Text] [Related]
33. Selective inhibition of FLT3 by gilteritinib in relapsed or refractory acute myeloid leukaemia: a multicentre, first-in-human, open-label, phase 1-2 study.
Perl AE; Altman JK; Cortes J; Smith C; Litzow M; Baer MR; Claxton D; Erba HP; Gill S; Goldberg S; Jurcic JG; Larson RA; Liu C; Ritchie E; Schiller G; Spira AI; Strickland SA; Tibes R; Ustun C; Wang ES; Stuart R; Röllig C; Neubauer A; Martinelli G; Bahceci E; Levis M
Lancet Oncol; 2017 Aug; 18(8):1061-1075. PubMed ID: 28645776
[TBL] [Abstract][Full Text] [Related]
34. A phase 1 study of the antibody-drug conjugate brentuximab vedotin with re-induction chemotherapy in patients with CD30-expressing relapsed/refractory acute myeloid leukemia.
Narayan R; Blonquist TM; Emadi A; Hasserjian RP; Burke M; Lescinskas C; Neuberg DS; Brunner AM; Hobbs G; Hock H; McAfee SL; Chen YB; Attar E; Graubert TA; Bertoli C; Moran JA; Bergeron MK; Foster JE; Ramos AY; Som TT; Vartanian MK; Story JL; McGregor K; Macrae M; Behnan T; Wey MC; Rae J; Preffer FI; Lesho P; Duong VH; Mann ML; Ballen KK; Connolly C; Amrein PC; Fathi AT
Cancer; 2020 Mar; 126(6):1264-1273. PubMed ID: 31860140
[TBL] [Abstract][Full Text] [Related]
35. Selinexor in Advanced, Metastatic Dedifferentiated Liposarcoma: A Multinational, Randomized, Double-Blind, Placebo-Controlled Trial.
Gounder MM; Razak AA; Somaiah N; Chawla S; Martin-Broto J; Grignani G; Schuetze SM; Vincenzi B; Wagner AJ; Chmielowski B; Jones RL; Riedel RF; Stacchiotti S; Loggers ET; Ganjoo KN; Le Cesne A; Italiano A; Garcia Del Muro X; Burgess M; Piperno-Neumann S; Ryan C; Mulcahy MF; Forscher C; Penel N; Okuno S; Elias A; Hartner L; Philip T; Alcindor T; Kasper B; Reichardt P; Lapeire L; Blay JY; Chevreau C; Valverde Morales CM; Schwartz GK; Chen JL; Deshpande H; Davis EJ; Nicholas G; Gröschel S; Hatcher H; Duffaud F; Herráez AC; Beveridge RD; Badalamenti G; Eriksson M; Meyer C; von Mehren M; Van Tine BA; Götze K; Mazzeo F; Yakobson A; Zick A; Lee A; Gonzalez AE; Napolitano A; Dickson MA; Michel D; Meng C; Li L; Liu J; Ben-Shahar O; Van Domelen DR; Walker CJ; Chang H; Landesman Y; Shah JJ; Shacham S; Kauffman MG; Attia S
J Clin Oncol; 2022 Aug; 40(22):2479-2490. PubMed ID: 35394800
[TBL] [Abstract][Full Text] [Related]
36. Quizartinib versus salvage chemotherapy in relapsed or refractory FLT3-ITD acute myeloid leukaemia (QuANTUM-R): a multicentre, randomised, controlled, open-label, phase 3 trial.
Cortes JE; Khaled S; Martinelli G; Perl AE; Ganguly S; Russell N; Krämer A; Dombret H; Hogge D; Jonas BA; Leung AY; Mehta P; Montesinos P; Radsak M; Sica S; Arunachalam M; Holmes M; Kobayashi K; Namuyinga R; Ge N; Yver A; Zhang Y; Levis MJ
Lancet Oncol; 2019 Jul; 20(7):984-997. PubMed ID: 31175001
[TBL] [Abstract][Full Text] [Related]
37. Selinexor-induced thrombocytopenia results from inhibition of thrombopoietin signaling in early megakaryopoiesis.
Machlus KR; Wu SK; Vijey P; Soussou TS; Liu ZJ; Shacham E; Unger TJ; Kashyap T; Klebanov B; Sola-Visner M; Crochiere M; Italiano JE; Landesman Y
Blood; 2017 Aug; 130(9):1132-1143. PubMed ID: 28630120
[TBL] [Abstract][Full Text] [Related]
38. Eltrombopag for advanced myelodysplastic syndromes or acute myeloid leukaemia and severe thrombocytopenia (ASPIRE): a randomised, placebo-controlled, phase 2 trial.
Mittelman M; Platzbecker U; Afanasyev B; Grosicki S; Wong RSM; Anagnostopoulos A; Brenner B; Denzlinger C; Rossi G; Nagler A; Garcia-Delgado R; Portella MSO; Zhu Z; Selleslag D
Lancet Haematol; 2018 Jan; 5(1):e34-e43. PubMed ID: 29241762
[TBL] [Abstract][Full Text] [Related]
39. Addition of the nuclear export inhibitor selinexor to standard intensive treatment for elderly patients with acute myeloid leukemia and high risk myelodysplastic syndrome.
Janssen JJWM; Löwenberg B; Manz M; Biemond BJ; Westerweel PE; Klein SK; Fehr M; Sinnige HAM; Efthymiou A; Legdeur MCJC; Pabst T; Gregor M; van der Poel MWM; Deeren D; Tick LW; Jongen-Lavrencic M; van Obbergh F; Boersma RS; de Weerdt O; Chalandon Y; Heim D; Spertini O; van Sluis G; Graux C; Stüssi G; van Norden Y; Ossenkoppele GJ
Leukemia; 2022 Sep; 36(9):2189-2195. PubMed ID: 35869267
[TBL] [Abstract][Full Text] [Related]
40. Guadecitabine (SGI-110) in treatment-naive patients with acute myeloid leukaemia: phase 2 results from a multicentre, randomised, phase 1/2 trial.
Kantarjian HM; Roboz GJ; Kropf PL; Yee KWL; O'Connell CL; Tibes R; Walsh KJ; Podoltsev NA; Griffiths EA; Jabbour E; Garcia-Manero G; Rizzieri D; Stock W; Savona MR; Rosenblat TL; Berdeja JG; Ravandi F; Rock EP; Hao Y; Azab M; Issa JJ
Lancet Oncol; 2017 Oct; 18(10):1317-1326. PubMed ID: 28844816
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
